Skip to main content

Table 2 Overall best response among all treated patients by BICR

From: Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Response Daratumumab 16 mg/kg (n = 32)
No. % 95% CI
ORR 8 25.0 11.5–43.4
Clinical benefit rate (CR + PR + stable disease) 14 43.8 26.4–62.3
CR 0 0  
PR 8 25.0  
Stable disease 6 18.8  
PD 14 43.8  
NE 4 12.5  
  1. BICR, blinded independent central review; CI, confidence interval; CR, complete response; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response
\